title: Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
abstract: Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-metastatic canine MCTs. Identification of toxicities and prognostic factors in these dogs was of secondary interest. Twenty-six dogs were included in this study. The overall response rate to masitinib was 50%. The median survival time for dogs that responded to masitinib was 630 days versus 137 days for dogs that did not respond (P = 0.0033). Toxicity was recorded in 61.5% of treated dogs, but the majority of adverse events were mild and self-limiting. Response to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs.
authors.affiliation: Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA.
authors.forename: O A
authors.initials: OA
authors.lastname: Smrkovski
authors.affiliation: Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA.
authors.forename: L
authors.initials: L
authors.lastname: Essick
authors.affiliation: Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA.
authors.forename: B W
authors.initials: BW
authors.lastname: Rohrbach
authors.affiliation: Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Legendre
mesh_terms: D000818:Animals; D001549:Benzamides; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D053208:Kaplan-Meier Estimate; D008297:Male; D034701:Mastocytosis, Cutaneous / Q000188:drug therapy / Q000662:veterinary*; D009367:Neoplasm Staging; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines; D012582:Schools, Veterinary; D012878:Skin Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D013714:Tennessee; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D013844:Thiazoles; C526575:masitinib
keywords: dog; mast cell; tyrosine kinase inhibitor